Substance p and its tachykinin NK1 receptor: A novel neuroprotective target for parkinson’s disease

Neural Regeneration Research

Volumn 10, Issue 9, 2015, Pages 1403-1405

  Thornton, Emma ^a,b   Vink, Robert ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA SYNUCLEIN; CADHERIN; CALCITONIN GENE RELATED PEPTIDE; CLAUDIN; JUNCTIONAL ADHESION MOLECULE; LEVODOPA; MULTIDRUG RESISTANCE PROTEIN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; OCCLUDIN; OXIDOPAMINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUBSTANCE P; TACHYKININ RECEPTOR;

ASTROCYTE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; LEUKOCYTE; MICROGLIA; MICROVASCULATURE; MOOD DISORDER; NEUROPROTECTION; NOTE; PARKINSON DISEASE; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 84942097378     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.165505     Document Type: Note

References (11)

1. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, Hunot S (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182-192.
2. Hawkins BT, Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57:173-185.
3. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57:176-179.
4. Liu CQ, Chen Z, Liu FX, Hu DN, Luo JH (2007) Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats. Neuropharmacology 53:832-841.
5. Pisani V, Stefani A, Pierantozzi M, Natoli S, Stanzione P, Franciotta D, Pisani A (2012) Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease. J Neuroinflammation 9:188.
6. Rite I, Machado A, Cano J, Venero JL (2007) Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 101:1567-1582.
7. Thornton E, Vink R (2012) Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson’s disease. PLoS One 7:e34138.
8. Thornton E, Tran TT, Vink R (2010) A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett 481:64-67.
9. Thornton E, Hassall MM, Corrigan F, Vink R (2014) The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model. Parkinsonism Relat Disord 20:508-513.
10. Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA (2006) Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 26:9448-9461.
11. Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F (2015) Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Exp Neurol 271:168-174.